Unnamed: 0,title,date,stock,sentiment
1189826.0,Stemline Therapeutics 13D From A. Menarini Shows 5.2% Stake,2020-05-13 14:51:00-04:00,STML,neutral
1189827.0,"Benzinga's Top Upgrades, Downgrades For May 5, 2020",2020-05-05 09:35:00-04:00,STML,positive
1189828.0,"Wedbush Downgrades Stemline Therapeutics to Neutral, Raises Price Target to $12.5",2020-05-05 08:54:00-04:00,STML,neutral
1189829.0,10 Biggest Price Target Changes For Tuesday,2020-05-05 08:15:00-04:00,STML,neutral
1189830.0,"Ladenburg Thalmann Downgrades Stemline Therapeutics to Neutral, Announces $12.5 Price Target",2020-05-05 08:02:00-04:00,STML,neutral
1189831.0,"HC Wainwright & Co. Downgrades Stemline Therapeutics to Neutral, Lowers Price Target to $12.5",2020-05-05 07:20:00-04:00,STML,negative
1189832.0,72 Biggest Movers From Yesterday,2020-05-05 04:29:00-04:00,STML,neutral
1189833.0,"Benzinga's Top Upgrades, Downgrades For May 4, 2020",2020-05-04 14:36:00-04:00,STML,positive
1189834.0,Mid-Afternoon Market Update: Crude Oil Gains 3%; Applied DNA Sciences Shares Spike Higher,2020-05-04 14:33:00-04:00,STML,neutral
1189835.0,"Cantor Fitzgerald Earlier Downgraded Stemline Therapeutics to Neutral, Raised Price Target to $12.5",2020-05-04 13:48:00-04:00,STML,neutral
1189836.0,55 Stocks Moving In Monday's Mid-Day Session,2020-05-04 12:39:00-04:00,STML,neutral
1189837.0,Mid-Day Market Update: Pitney Bowes Slides Following Q1 Earnings; Stemline Therapeutics Shares Surge,2020-05-04 12:27:00-04:00,STML,positive
1189838.0,Mid-Morning Market Update: Markets Mostly Lower; Tyson Foods Misses Q2 Expectations,2020-05-04 10:18:00-04:00,STML,negative
1189839.0,Stemline Therapeutics To Go Private In $667M Transaction,2020-05-04 10:16:00-04:00,STML,neutral
1189840.0,Stemline Therapeutics to be Acquired for $11.50/Share Cash and Up to $1/Share in Contingent Value Right by Menarini Group,2020-05-04 07:04:00-04:00,STML,positive
1189841.0,80 Biggest Movers From Yesterday,2020-03-31 04:15:00-04:00,STML,neutral
1189842.0,55 Stocks Moving In Monday's Mid-Day Session,2020-03-30 12:49:00-04:00,STML,neutral
1189843.0,"Cantor Fitzgerald Reiterates Overweight on Stemline Therapeutics, Lowers Price Target to $10",2020-03-27 07:36:00-04:00,STML,negative
1189844.0,"JP Morgan Maintains Overweight on Stemline Therapeutics, Lowers Price Target to $8",2020-03-26 10:22:00-04:00,STML,negative
1189845.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,STML,neutral
1189846.0,"Wedbush Maintains Outperform on Stemline Therapeutics, Lowers Price Target to $11",2020-03-17 11:32:00-04:00,STML,negative
1189847.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,STML,neutral
1189848.0,"HC Wainwright & Co. Maintains Buy on Stemline Therapeutics, Lowers Price Target to $18",2020-03-17 07:28:00-04:00,STML,negative
1189849.0,"The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review",2020-03-15 09:55:00-04:00,STML,neutral
1189850.0,"Stemline Therapeutics Q4 EPS $(0.38) Up From $(0.92) YoY, Sales $11.8M",2020-03-13 16:48:00-04:00,STML,neutral
1189851.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,STML,negative
1189852.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,STML,negative
1189853.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,STML,negative
1189854.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,STML,positive
1189855.0,Stocks That Hit 52-Week Lows On Tuesday,2020-03-10 10:37:00-04:00,STML,negative
1189856.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,STML,negative
1189857.0,Stocks That Hit 52-Week Lows On Friday,2020-03-06 11:22:00-05:00,STML,negative
1189858.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,STML,negative
1189859.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,STML,neutral
1189860.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,STML,negative
1189861.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,STML,positive
1189862.0,"H.C. Wainwright Reiterates Buy on Stemline Therapeutics, Lowers Price Target to $20",2020-01-21 07:58:00-05:00,STML,negative
1189863.0,"Wedbush Maintains Outperform on Stemline Therapeutics, Lowers Price Target to $14",2020-01-16 08:07:00-05:00,STML,negative
1189864.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,STML,negative
1189865.0,80 Biggest Movers From Yesterday,2020-01-15 04:48:00-05:00,STML,neutral
1189866.0,Mid-Afternoon Market Update: Dow Turns Lower; Stemline Therapeutics Shares Plummet,2020-01-14 14:15:00-05:00,STML,neutral
1189867.0,Mid-Day Market Update: GameStop Falls Following Soft 2019 Holiday Sales; RTI Surgical Shares Climb,2020-01-14 12:26:00-05:00,STML,positive
1189868.0,48 Stocks Moving In Tuesday's Mid-Day Session,2020-01-14 12:06:00-05:00,STML,neutral
1189869.0,Mid-Morning Market Update: Markets Mostly Lower; JPMorgan Tops Q4 Expectations,2020-01-14 10:27:00-05:00,STML,positive
1189870.0,"The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug",2020-01-14 07:55:00-05:00,STML,positive
1189871.0,26 Stocks Moving in Tuesday's Pre-Market Session,2020-01-14 07:41:00-05:00,STML,neutral
1189872.0,"CORRECTION: Stemline Therapeutics Sees Q4 Sees Prelim. Q4 Net Revenues For ELZONRIS $11.8M; A Prior Headline Indicated This Was The FY19 Estimate, This Was Incorrect",2020-01-13 16:26:00-05:00,STML,neutral
1189873.0,Stemline Therapeutics shares are trading lower after the company issued preliminary Q4 net revenues for ELZONRIS at $11.8 million and $43.2 million in FY19.,2020-01-13 16:24:00-05:00,STML,neutral
1189874.0,"Stemline Therapeutics Sees Prelim. Q4 Net Revenues For ELZONRIS $11.8M, Sees $43.2M In FY19",2020-01-13 16:21:00-05:00,STML,neutral
1189875.0,"Benzinga's Top Upgrades, Downgrades For December 24, 2019",2019-12-24 10:49:00-05:00,STML,positive
1189876.0,"Cantor Fitzgerald Initiates Coverage On Stemline Therapeutics with Overweight Rating, Announces $18 Price Target",2019-12-24 06:17:00-05:00,STML,negative
1189877.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,STML,positive
1189878.0,Stemline Therapeutics Highlights Upcoming Presentations At ASH Dec. 7-10,2019-12-06 07:03:00-05:00,STML,neutral
1189879.0,"Wedbush Maintains Outperform on Stemline Therapeutics, Lowers Price Target to $17",2019-11-11 08:05:00-05:00,STML,negative
1189880.0,80 Biggest Movers From Friday,2019-11-11 04:51:00-05:00,STML,neutral
1189881.0,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut",2019-11-08 08:14:00-05:00,STML,neutral
1189882.0,"Stemline Therapeutics Q3 EPS $(0.34) Beats $(0.45) Estimate, Sales $13.3M Miss $13.64M Estimate",2019-11-07 17:13:00-05:00,STML,negative
1189883.0,Stemline Therapeutics Announces ELZONRIS Clinical Data Selected For Oral Presentation At 81st Annual Meeting Of The Japanese Society Of Hematology,2019-10-08 07:34:00-04:00,STML,neutral
1189884.0,Stemline Therapeutics To Highlight SL-801 Data At ESMO,2019-09-27 07:31:00-04:00,STML,positive
1189885.0,52 Biggest Movers From Yesterday,2019-09-19 05:18:00-04:00,STML,neutral
1189886.0,36 Stocks Moving In Wednesday's Mid-Day Session,2019-09-18 13:19:00-04:00,STML,neutral
1189887.0,60 Biggest Movers From Yesterday,2019-08-22 05:12:00-04:00,STML,neutral
1189888.0,31 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-09 09:00:00-04:00,STML,neutral
1189889.0,Stocks That Set New 52-Week Highs Thursday,2019-08-08 12:19:00-04:00,STML,neutral
1189890.0,52 Stocks Moving In Thursday's Pre-Market Session,2019-08-08 07:49:00-04:00,STML,neutral
1189891.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,STML,neutral
1189892.0,42 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-07 21:24:00-04:00,STML,neutral
1189893.0,Stemline Therapeutics shares are trading lower after the company reported a 5 million share common stock offering.,2019-08-07 16:31:00-04:00,STML,positive
1189894.0,Stemline Therapeutics Reports 5M Share Common Stock Offering,2019-08-07 16:27:00-04:00,STML,positive
1189895.0,85 Biggest Movers From Yesterday,2019-08-07 05:39:00-04:00,STML,neutral
1189896.0,"Stemline Therapeutics Reports Centers For Medicare, Medicaid Services Granted New Technology Add-On Payment To EZLONRIS",2019-08-06 08:22:00-04:00,STML,positive
1189897.0,82 Biggest Movers From Friday,2019-08-05 05:40:00-04:00,STML,neutral
1189898.0,60 Stocks Moving In Friday's Mid-Day Session,2019-08-02 13:43:00-04:00,STML,neutral
1189899.0,"Stemline Therapeutics Q2 EPS $(0.42) Up From $(0.66) YoY, Sales $13.007M Up From $500K YoY",2019-08-02 07:12:00-04:00,STML,neutral
1189900.0,"Stemline Therapeutics Announces Presentation of ELZONRIS Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress",2019-06-17 07:46:00-04:00,STML,negative
1189901.0,Stemline Therapeutics Highlights 3 Presentations Of ELZONRIS At European Hematology Association Congress,2019-06-13 07:33:00-04:00,STML,neutral
1189902.0,Stemline Therapeutics Highlights ASCO Presentation Of ELZONRIS Phase 2 Clinical Data In CMML And MF; Provides Next Steps For CMML Program,2019-06-03 07:35:00-04:00,STML,neutral
1189903.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,STML,neutral
1189904.0,Stemline Therapeutics Reports ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress,2019-05-20 07:06:00-04:00,STML,neutral
1189905.0,Stemline Therapeutics Highlights ELZONRIS Data Selected For Presentation At ASCO,2019-05-16 07:17:00-04:00,STML,neutral
1189906.0,Wedbush: Trajectory For Stemline Therapeutics' Blood Cancer Drug Priced Into Stock,2019-05-13 10:02:00-04:00,STML,negative
1189907.0,"Wedbush Downgrades Stemline Therapeutics, Inc. - Common Stock to Neutral",2019-05-13 07:53:00-04:00,STML,neutral
1189908.0,"The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales",2019-05-10 08:00:00-04:00,STML,negative
1189909.0,"Stemline Therapeutics Q1 EPS $(0.73) Misses $(0.63) Estimate, Sales $5.049M Beat $2.36M Estimate",2019-05-10 06:36:00-04:00,STML,negative
1189910.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,STML,positive
1189911.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-18 10:51:00-04:00,STML,negative
1189912.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-17 10:31:00-04:00,STML,negative
1189913.0,"7 Stocks To Watch For March 18, 2019",2019-03-18 05:19:00-04:00,STML,neutral
1189914.0,Stemline Therapeutics Q4 EPS $(0.92) Misses $(0.74) Estimate,2019-03-15 16:02:00-04:00,STML,negative
1189915.0,56 Biggest Movers From Yesterday,2019-03-13 06:04:00-04:00,STML,neutral
1189916.0,Stemline Therapeutics Licenses Worldwide Rights to a Novel Selective RET Inhibitor,2019-03-11 07:10:00-04:00,STML,positive
1189917.0,Stemline Therapeutics Announces Validation Of Marketing Authorization Application By The European Medicines Agency,2019-01-30 07:35:00-05:00,STML,neutral
1189918.0,25 Stocks Moving In Wednesday's Pre-Market Session,2019-01-16 08:12:00-05:00,STML,neutral
1189919.0,55 Biggest Movers From Yesterday,2019-01-16 05:12:00-05:00,STML,neutral
1189920.0,Stemline Therapeutics Prices Upsized 8.8M Share Public Offering of Common Stock @$9/Share,2019-01-16 03:51:00-05:00,STML,positive
1189921.0,40 Stocks Moving In Tuesday's Mid-Day Session,2019-01-15 12:36:00-05:00,STML,neutral
1189922.0,24 Stocks Moving In Tuesday's Pre-Market Session,2019-01-15 08:00:00-05:00,STML,neutral
1189923.0,6 Stocks Moving In Monday's After-Hours Session,2019-01-14 17:16:00-05:00,STML,neutral
1189924.0,Stemline Therapeutics shares are trading lower after the company announced an offering of 6.6 million shares of common stock.,2019-01-14 16:43:00-05:00,STML,positive
1189925.0,Stemline Therapeutics Reports Offering Of 6.6M Shares Of Common Stock,2019-01-14 16:36:00-05:00,STML,positive
1189926.0,Stemline Therapeutics Announces Submission Of European Marketing Authorization Application For ELZONRIS,2019-01-07 09:51:00-05:00,STML,neutral
1189927.0,20 Stocks Moving In Thursday's Pre-Market Session,2018-12-27 08:05:00-05:00,STML,neutral
1189928.0,"Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation",2018-12-26 12:31:00-05:00,STML,neutral
1189929.0,Stemline Therapeutics Issues Press Release Confirming FDA Approval OF ELZONRIS For Treatment Of Blastic Plasmacytoid Dendritic Cell Neoplasm,2018-12-21 14:57:00-05:00,STML,positive
1189930.0,FDA Approves Stemline Therapeutics' ELZONARIS Infusion For Treatment Of Blastic Plasmacytoid Dendritic Cell Neoplasm,2018-12-21 10:27:00-05:00,STML,positive
1189931.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,STML,neutral
1189932.0,JP Morgan Initiates Coverage On Stemline Therapeutics with Overweight Rating,2018-12-11 09:54:00-05:00,STML,neutral
1189933.0,Stemline Therapeutics Option Alert: Jan 18 $10 Calls at the Ask: 680 @ $1.7 vs 651 OI; Ref=$10.6851,2018-11-30 12:27:00-05:00,STML,positive
1189934.0,"The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings",2018-11-30 08:25:00-05:00,STML,negative
1189935.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 28, 2018",2018-11-29 10:59:00-05:00,STML,negative
1189936.0,48 Biggest Movers From Yesterday,2018-11-28 05:00:00-05:00,STML,neutral
1189937.0,"Benzinga's Top Upgrades, Downgrades For November 26, 2018",2018-11-26 09:01:00-05:00,STML,positive
1189938.0,PiperJaffray Initiates Coverage On Stemline Therapeutics with Overweight Rating,2018-11-26 07:11:00-05:00,STML,negative
1189939.0,"The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings",2018-11-25 09:41:00-05:00,STML,neutral
1189940.0,50 Biggest Movers From Wednesday,2018-11-23 05:17:00-05:00,STML,neutral
1189941.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018",2018-11-20 09:12:00-05:00,STML,negative
1189942.0,"The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings",2018-11-20 08:29:00-05:00,STML,negative
1189943.0,Stemline Therapeutics Announces EMA Grants Accelerated Assessment For Planned Elzonris Marketing Authorization Application,2018-11-20 07:05:00-05:00,STML,positive
1189944.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,STML,positive
1189945.0,"The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut",2018-11-14 08:17:00-05:00,STML,neutral
1189946.0,"The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut",2018-11-13 07:54:00-05:00,STML,negative
1189947.0,Stemline Therapeutics Q3 EPS $(0.73) Misses $(0.67) Estimate,2018-11-08 16:51:00-05:00,STML,negative
1189948.0,Court Filing Shows A US Judge Has Blocked State Of Texas's Fetal Tissue Burial Law,2018-09-05 15:08:00-04:00,STML,negative
1189949.0,Benzinga Pro's 5 Stocks To Watch Today,2018-08-13 09:25:00-04:00,STML,neutral
1189950.0,Stemline Therapeutics Announces that FDA Accepts ELZONRIS Biologics License Application and Grants Priority Review,2018-08-13 06:31:00-04:00,STML,positive
1189951.0,Stemline Therapeutics Q2 EPS $(0.66) Misses $(0.64) Estimate,2018-08-09 08:00:00-04:00,STML,negative
1189952.0,Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS,2018-06-25 07:00:00-04:00,STML,neutral
1189953.0,"Stemline Therapeutics Reports Clinical Data from ELZONRISTM Trials in BPDCN, CMML and MF Delivered at the EHA Congress",2018-06-18 07:02:00-04:00,STML,neutral
1189954.0,"Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug",2018-06-15 09:13:00-04:00,STML,neutral
1189955.0,Stemline Therapeutics Announces Positive Data Presentations On SL-701 And SL-801 At ASCO,2018-06-05 07:11:00-04:00,STML,positive
1189956.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,STML,negative
1189957.0,"Benzinga's Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy's Revenue Miss, FDA Warns E-Liquid Makers Again",2018-05-11 08:21:00-04:00,STML,negative
1189958.0,"Stemline Therapeutics Q1 EPS $(0.69), Inline",2018-05-09 16:01:00-04:00,STML,neutral
1189959.0,Stemline Therapeutics Reports Start of Rolling BLA Submission for SL-401,2018-04-05 07:02:00-04:00,STML,neutral
1189960.0,"Stemline Therapeutics Reports Q4 EPS $(0.93) Misses $(0.70) Est., No Sales",2018-03-16 07:35:00-04:00,STML,negative
1189961.0,Stemline Therapeutics Prices 3.7M Share Common Stock Offering At $14/Share,2018-01-24 07:02:00-05:00,STML,positive
1189962.0,Stemline Therapeutics Announces 3.7M Shares Common Stock Offering,2018-01-22 16:01:00-05:00,STML,positive
1189963.0,"Stemline Therapeutics Offers SL-401 Phase 1/2 Trial Outcomes For MPN, AML",2017-12-13 08:48:00-05:00,STML,positive
1189964.0,UPDATE: Stemline Says BLA Submission Preparation For SL-401 Underway,2017-12-13 08:45:00-05:00,STML,neutral
1189965.0,"Stemline Therapeutics Reports Presentation Of Detailed SL-401 Pivotal Data At ASH: Primary Endpoint In BPDCN Met, Median Overall Survival Not Reached In First-Line Patients",2017-12-13 08:45:00-05:00,STML,negative
1189966.0,Stemline Therapeutics Highlights Will Offer 4 SL-401 Presentations At ASH,2017-12-08 07:01:00-05:00,STML,neutral
1189967.0,"Stemline Therapeutics Reports Q3 EPS $(0.68) vs. $(0.61) Est., $299.4K vs. $170K Est.",2017-11-09 16:02:00-05:00,STML,neutral
1189968.0,46 Biggest Movers From Yesterday,2017-11-01 05:27:00-04:00,STML,neutral
1189969.0,38 Stocks Moving In Tuesday's Mid-Day Session,2017-10-31 12:31:00-04:00,STML,neutral
1189970.0,"Stemline Therapeutics Shares Hit A High Of $12.54 Premarket On Report That Co. Met Primary Endpoint In SL-401 Trial, Shares Have Since Pulled Back From Premarket Highs To $10.94, Up 3.7%",2017-10-31 08:24:00-04:00,STML,positive
1189971.0,"Stemline Therapeutics Q2 EPS $(0.66) vs $(0.48) Est., Sales $299.4K vs $200.0K Est.",2017-08-08 07:24:00-04:00,STML,neutral
1189972.0,15 Biggest Mid-Day Gainers For Friday,2017-06-23 12:26:00-04:00,STML,neutral
1189973.0,Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN,2017-06-23 09:37:00-04:00,STML,neutral
1189974.0,Stemline Therapeutics Expected To Deliver Update On Phase 2 Data For SL-401 at EHA Today,2017-06-23 08:35:00-04:00,STML,neutral
1189975.0,"Companies Holding Shareholder Meetings Today Include Monster Beverage, Stemline Therapeutics, and Century Aluminum",2017-06-19 08:53:00-04:00,STML,neutral
1189976.0,22 Stocks Moving In Friday's Pre-Market Session,2017-06-16 08:28:00-04:00,STML,neutral
1189977.0,Stemline Therapeutics to Present SL-401 Updated Data from Stage 1d 2 of Ongoing Pivotal Phase 2 BPDCN Trial at EHA Meeting; Says Remains On Track to Provide  Update on BPDCN Patients Enrolled in Stage 3 of Phase 2 Pivotal Trial in H2 of This Year,2017-05-18 07:38:00-04:00,STML,neutral
1189978.0,"Stemline Therapeutics Reports Q1 EPS $(0.67) vs $(0.47) Est., Grant Sales $299.4K vs $150K Est.",2017-05-10 17:19:00-04:00,STML,positive
1189979.0,Expect Stemline To Generate Acquisition Interest As SL-401 Approval Decision Nears,2017-03-23 15:20:00-04:00,STML,positive
1189980.0,7 Biggest Price Target Changes For Monday,2017-02-06 09:57:00-05:00,STML,neutral
1189981.0,Why A Patient Death Doesn't Necessarily Scuttle Stemline's Chances For SL-401 Approval,2017-02-06 08:49:00-05:00,STML,neutral
1189982.0,A First Take On Stemline's Pivotal BPDCN Study Patient Death,2017-02-03 13:41:00-05:00,STML,negative
1189983.0,25 Stocks Moving In Friday's Pre-Market Session,2017-02-03 08:12:00-05:00,STML,neutral
1189984.0,Adam Feuerstein Tweets: $STML confirms it received report of patient death on Jan. 18. But co. DID NOT disclose death to investors who bought their deal on Jan. 19.,2017-02-02 15:33:00-05:00,STML,negative
1189985.0,"Stemline Therapeutics Provides Update on Pivotal BPDCN Trial, Says Co. Received A Report Of Patient Death On Jan. 18th Due To CLS Which Is A Side Effect Of SL-401",2017-02-02 15:26:00-05:00,STML,negative
1189986.0,"Cowen Defending Stemline, Says Today's Move Is Huge Overreaction, Says Ontak's Label Has Black Box Warning For CLS And Mentions Cases Of Death Due To CLS, Yet FDA Didn't Pull Drug Off Market",2017-02-02 14:25:00-05:00,STML,negative
1189987.0,18 Biggest Mid-Day Losers For Thursday,2017-02-02 12:50:00-05:00,STML,negative
1189988.0,"Adam Feuerstein @adamfeuerstein Tweet: Side Effect Kills Cancer Patient in $STML Drug Trial, the Company Raises Money thestreet.com/story/13975695",2017-02-02 06:19:00-05:00,STML,negative
1189989.0,15 Biggest Mid-Day Losers For Friday,2017-01-20 13:01:00-05:00,STML,negative
1189990.0,Stemline Therapeutics Prices Offering Of 4.5M Shares At $10/Share,2017-01-20 09:01:00-05:00,STML,positive
1189991.0,Hearing Stemline Therapeutics Offering of 3.2M Shares Priced at $10/Share,2017-01-20 08:44:00-05:00,STML,positive
1189992.0,18 Stocks Moving In Friday's Pre-Market Session,2017-01-20 08:18:00-05:00,STML,neutral
1189993.0,Stemline Therapeutics Reports Proposed Public Offering of Common Stock,2017-01-19 16:04:00-05:00,STML,neutral
1189994.0,Mid-Afternoon Market Update: AZZ Drops On Weak Q3 Results; Stemline Shares Spike Higher,2017-01-06 14:22:00-05:00,STML,negative
1189995.0,15 Biggest Mid-Day Gainers For Friday,2017-01-06 12:51:00-05:00,STML,neutral
1189996.0,Mid-Day Market Update: Dow Gains 50 Points; Ruby Tuesday Shares Fall Following Q2 Results,2017-01-06 12:00:00-05:00,STML,positive
1189997.0,Mid-Morning Market Update: Markets Mixed; Greenbrier Profit Misses Views,2017-01-06 10:02:00-05:00,STML,positive
1189998.0,18 Stocks Moving In Friday's Pre-Market Session,2017-01-06 08:25:00-05:00,STML,neutral
1189999.0,"UPDATE: Stemline Says BLA Filing is Targeted for 2H'17, Commercial Launch Projected for '18",2017-01-05 16:32:00-05:00,STML,neutral
1190000.0,"UPDATE: Stemline Says Apprx. Half of New Cohort Patients Already Enrolled, Full Enrollment Expected This Qtr.",2017-01-05 16:32:00-05:00,STML,neutral
1190001.0,Stemline Reports FDA Deal on Expedited Pathway to Full Approval of SL-401 in First-Line BPDCN,2017-01-05 16:31:00-05:00,STML,positive
1190002.0,"Stemline Therapeutics Reports Results from Ongoing Phase 2 Trial in AML in Remission with MRD: SL-401 Found to be Safe, Well Tolerated, Side Effects Predictable, Manageable",2016-12-06 11:49:00-05:00,STML,positive
1190003.0,"American Society Of Hematology (ASH) Meeting Presenters Tonight Include Karyopharm, bluebird bio, Alnylam, Juno Therapeutics, Stemline Therapeutics, Kite Pharma, Beigene, & Prothena",2016-12-05 15:09:00-05:00,STML,neutral
1190004.0,"American Society Of Hematology Meeting Begins Dec. 3rd, Day 1 of 4",2016-12-02 10:53:00-05:00,STML,neutral
1190005.0,"Stemline Therapeutics Reports Q3 EPS $(0.56) vs $(0.54) Est., Sales $299.401K vs $180K Est.",2016-11-08 07:02:00-05:00,STML,neutral
1190006.0,Stocks Hitting 52-Week Highs,2016-10-11 10:09:00-04:00,STML,neutral
1190007.0,"15 Stocks That Rallied 4 Days, Then Sold Off Yesterday",2016-09-29 07:13:00-04:00,STML,neutral
1190008.0,"15 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-08-31 13:17:00-04:00,STML,neutral
1190009.0,Stemline Therapeutics Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for SL-401,2016-08-23 07:30:00-04:00,STML,neutral
1190010.0,Stemline Therapeutics Reports Q2 EPS $(0.52) vs. Est. $(0.55),2016-08-04 07:59:00-04:00,STML,neutral
1190011.0,Stemline Therapeutics Announces SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at #ASCO16; Says High Response Rates Demonstrated Across All Lines As Enrollment Proceeds,2016-06-04 21:30:00-04:00,STML,neutral
1190012.0,"Stemline Therapeutics' SL-401 Phase 2 BPDCN Data Selected for Oral Presentations at the Upcoming ASCO, EHA Meetings",2016-05-19 07:32:00-04:00,STML,neutral
1190013.0,"Stemline Therapeutics Q1 EPS ($0.51) vs ($0.59) est, Revenue $205.65K vs $150.00K est",2016-05-09 08:04:00-04:00,STML,neutral
1190014.0,Stemline Therapeutics Reports Q4 EPS $(0.58) vs. Est. $(0.57),2016-03-14 07:34:00-04:00,STML,neutral
1190015.0,Stemline Therapeutics Reports Opening of SL-801 IND,2015-12-22 08:05:00-05:00,STML,neutral
1190016.0,"Stemline Therapeutics Presents Clinical Update From Ongoing SL-401 Pivotal BPDCN Trial, Produced 86% Overall Response Rate",2015-12-07 11:24:00-05:00,STML,neutral
1190017.0,"Stemline Reports Five Presentations, Will Offer Update on SL-401 Trial from Ongoing Pivotal BPDCN Trial at ASH Meeting",2015-12-04 08:02:00-05:00,STML,neutral
1190018.0,Stemline Reports EU Orphan Drug Designation for SL-401 for Treatment of Acute Myeloid Leukemia,2015-09-10 08:01:00-04:00,STML,neutral
1190019.0,"Stemline Therapeutics Reports Q2 Loss $0.58 Vs Est Loss $0.41, Sales $121.4K Vs Est $80.0K",2015-08-10 16:15:00-04:00,STML,negative
1190020.0,"Stemline Therapeutics Offers Top-Line Results from Lead-In Stage of Ongoing BPDCN Pivotal Trial: Says SL-401 Showed Multi-Cycle Safety, Efficacy",2015-05-28 16:16:00-04:00,STML,positive
1190021.0,Stemline Therapeutics Reports Q1 Loss of $0.46/Share vs Loss of $0.43/Share Est.,2015-05-11 08:26:00-04:00,STML,negative
1190022.0,HC Wainwright Initiates Stemline Therapeutics At Buy,2015-04-27 09:31:00-04:00,STML,neutral
1190023.0,H.C. Wainwright Initiates Stemline Therapeutics With Buy,2015-04-27 09:17:00-04:00,STML,neutral
1190024.0,Benzinga's Top Initiations,2015-04-27 09:17:00-04:00,STML,positive
1190025.0,"H.C. Wainwright Initiates Coverage on Stemline Therapeutics at Buy, Announces $38.00 PT",2015-04-27 07:06:00-04:00,STML,neutral
1190026.0,Biotech Stocks Moving Higher,2015-02-23 15:35:00-05:00,STML,neutral
1190027.0,Wedbush Weighs In On Medivation Following Phase II TERRAIN Study Results,2015-02-03 11:01:00-05:00,STML,neutral
1190028.0,Stemline Therapeutics Announces SL-701 Granted Orphan Drug Designation for the Treatment of Glioma,2015-01-30 08:34:00-05:00,STML,positive
1190029.0,What Investors Are Looking At In The Stem Cell Sector,2015-01-13 11:48:00-05:00,STML,neutral
1190030.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4,2015-01-13 11:34:00-05:00,STML,neutral
1190031.0,Mid-Morning Market Update: Markets Jump; Family Dollar Profit Misses Estimates,2015-01-08 11:39:00-05:00,STML,positive
1190032.0,Morning Market Losers,2015-01-08 09:54:00-05:00,STML,negative
1190033.0,Stemline Therapeutics Prices 3.8M Shares at $15.75/Share,2015-01-08 09:06:00-05:00,STML,positive
1190034.0,Stemline Therapeutics Announces Public Offering of Common Stock,2015-01-07 16:05:00-05:00,STML,neutral
1190035.0,Stemline Therapeutics In-Licenses Novel Oral Small Molecule Nuclear Transport Inhibitor Targeting XPO1,2015-01-07 16:01:00-05:00,STML,positive
1190036.0,What Investors Are Looking For In Brainstorm Cell Therapeutics' Upcoming Clinical Results,2014-12-31 16:02:00-05:00,STML,neutral
1190037.0,Stemline Therapeutics Initiates SL-401 Clinical Trial In Four Rare Myeloproliferative Neoplasms,2014-12-16 10:36:00-05:00,STML,neutral
1190038.0,Stemline Therapeutics Reports Q3 EPS of $(0.53) vs $(0.58) Est,2014-11-12 07:09:00-05:00,STML,neutral
1190039.0,"Stemline Therapeutics Initiates SL-401 Trial In AML Patients In First Complete Response With Minimal Residual Disease, The Second SL-401 Trial Initiated In 2H14",2014-10-16 07:03:00-04:00,STML,positive
1190040.0,"Stemline Therapeutics Chairman Bergstein Buys 2,000 Shares @$11.05/Share -Form 4",2014-09-03 12:51:00-04:00,STML,positive
1190041.0,Stemline Therapeutics Reports Q2 EPS of $(0.47) vs $(0.69) Est,2014-08-14 07:03:00-04:00,STML,neutral
1190042.0,Events Scheduled for Week of Jun. 16th to Jun. 20th,2014-06-17 10:48:00-04:00,STML,neutral
1190043.0,Stemline Therapeutics Announces Presentation of SL-401 Preclinical Efficacy Data in Multiple Myeloma at ASCO,2014-05-20 07:03:00-04:00,STML,neutral
1190044.0,US Stock Futures Drop; Alcoa Earnings In Focus,2014-04-08 07:25:00-04:00,STML,negative
1190045.0,Stemline Therapeutics Announces FDA Acceptance of IND for SL-701,2014-04-08 07:02:00-04:00,STML,positive
1190046.0,Stemline Therapeutics Announces FDA Acceptance of IND for SL-701,2014-04-08 07:02:00-04:00,STML,positive
1190047.0,Amended 13G Filing from SAC Capital on Stemline Therapeutics Shows Reduced Stake from 5.39% as of Dec. 31st to 2.7%,2014-04-03 16:14:00-04:00,STML,neutral
1190048.0,Stemline Therapeutics to Present SL-501 Preclinical Efficacy Data in TKI-Resistant CML at AACR,2014-04-01 07:04:00-04:00,STML,neutral
1190049.0,Stemline Therapeutics Files $150M Mixed Securities Shelf,2014-02-03 16:55:00-05:00,STML,positive
1190050.0,Stemline Therapeutics Present Clinical Trial Results of Synthetic Peptide Vaccine for Brain Cancer at SNO Annual Meeting ,2013-11-23 08:50:00-05:00,STML,negative
1190051.0,Stemline Therapeutics Reports Clinical Trial Results w SL-701,2013-11-19 08:02:00-05:00,STML,neutral
1190052.0,UPDATE: Aegis Capital Reiterates on Stemline Therapeutics Ahead of ASH Annual Meeting,2013-11-13 10:49:00-05:00,STML,neutral
1190053.0,Stemline Therapeutics Shares Spike Higher; May be Attributed to Aegis Capital Raising PT from $40 to $70,2013-10-30 13:20:00-04:00,STML,positive
1190054.0,Stemline Therapeutics Spikes Higher,2013-10-23 14:10:00-04:00,STML,neutral
1190055.0,Stemline Files to Withdraw S-1 for Offering,2013-10-23 14:09:00-04:00,STML,neutral
1190056.0,UPDATE: Wedbush Initiates Coverage on Stemline Therapeutics on Strong SL-401 Potential,2013-09-12 09:30:00-04:00,STML,positive
1190057.0,"Wedbush Initiates Coverage on Stemline Therapeutics at Outperform, Announces $49.00 PT",2013-09-12 08:10:00-04:00,STML,neutral
1190058.0,"Wedbush Initiates Coverage on Stemline Therapeutics at Outperform, Announces $49.00 PT",2013-09-11 16:34:00-04:00,STML,neutral
1190059.0,Benzinga's Top Initiations,2013-08-29 09:04:00-04:00,STML,positive
1190060.0,UPDATE: Jefferies Initiates Coverage on Stemline Therapeutics Ahead of SL-401 Trials,2013-08-29 08:40:00-04:00,STML,neutral
1190061.0,"Jefferies Initiates Coverage on Stemline Therapeutics at Buy, Announces $60.00 PT",2013-08-29 06:30:00-04:00,STML,neutral
1190062.0,Benzinga's Top Initiations,2013-07-30 09:11:00-04:00,STML,positive
1190063.0,"Roth Capital Initiates Coverage on Stemline Therapeutics at Buy, Announces $50.00 PT",2013-07-30 08:46:00-04:00,STML,neutral
1190064.0,Stemline Therapeutics Added to Russell 3000(R) Index,2013-07-01 08:10:00-04:00,STML,neutral
1190065.0,"Aegis Capital Maintains Buy on Stemline Therapeutics, Raises PT to $40.00",2013-06-21 11:18:00-04:00,STML,neutral
1190066.0,UPDATE: Aegis Capital Raises PT on Stemline Therapeutics Following Recent Progress,2013-06-21 10:35:00-04:00,STML,positive
1190067.0,"Ladenburg Thalmann Initiates Coverage on Stemline Therapeutics at Buy, Announces $36.00 PT",2013-06-18 09:09:00-04:00,STML,neutral
1190068.0,Stocks Hitting 52-Week Highs,2013-06-13 10:30:00-04:00,STML,neutral
1190069.0,Stemline Therapeutics Closes $60M Offering of Common Shares,2013-05-22 09:32:00-04:00,STML,positive
1190070.0,Stemline Therapeutics Prices 4.1M Shares at $14.50/Share,2013-05-16 17:48:00-04:00,STML,positive
1190071.0,Aegis Capital Initiates Stemline Therapeutics at Buy on Attractive Valuation,2013-03-18 13:30:00-04:00,STML,positive
1190072.0,"Aegis Capital Initiates Coverage on Stemline Therapeutics at Buy, Announces $35.00 PT",2013-03-18 09:12:00-04:00,STML,neutral
1190073.0,"WBB Securities Initiates Coverage on Stemline Therapeutics at Sell, Announces $9.00 PT",2013-02-12 09:50:00-05:00,STML,positive
1190074.0,Stocks Hitting 52-Week Lows,2013-02-01 10:14:00-05:00,STML,negative
1190075.0,"Stemline Therapeutics Shares Open for Trade ~$11.30, Priced at $10",2013-01-29 10:26:00-05:00,STML,positive
1190076.0,"Stemline Therapeutics Raises IPO Share Amount from 1.82M Shares to 2.275M Shares, Price Will Be in $10-12/Share Range",2013-01-08 17:41:00-05:00,STML,positive
